Literature DB >> 25170220

Decreased expression of miR-133a correlates with poor prognosis in colorectal cancer patients.

Li-Li Wang1, Lu-Tao Du1, Juan Li1, Yi-Min Liu1, Ai-Lin Qu1, Yong-Mei Yang1, Xin Zhang1, Gui-Xi Zheng1, Chuan-Xin Wang1.   

Abstract

AIM: To investigate microRNA-133a (miR-133a) expression in colorectal cancer (CRC) and its relationship with tumorigenesis and disease prognosis.
METHODS: Quantitative real-time polymerase chain reaction was used to measure levels of miR-133a in tumor samples and adjacent non-cancerous tissues from 169 patients undergoing radical resection for CRC. The associations between miR-133a expression and patient age, sex, as well as clinicopathologic parameters, such as tumor size, differentiation, location, invasion depth, metastasis, tumor-node-metastasis (TNM) stage and overall patient survival, were analyzed by Mann-Whitney U and Kruskal-Wallis tests. The Kaplan-Meier method and Cox proportional hazards regression analyses were performed to estimate the prognostic factors for patient survival prediction.
RESULTS: The expression of miR-133a was significantly downregulated in CRC tissues compared with adjacent non-cancerous tissues (P < 0.05). This reduction was associated with the depth of the local invasion, poor differentiation, lymph node metastasis and advanced disease (P < 0.05). Moreover, Kaplan-Meier analysis demonstrated that patients with low miR-133a expression had poorer overall survival (OS) than those with high miR-133a expression (P < 0.001). Univariate analysis revealed statistically significant correlations between OS and miR-133a level, tumor local invasion, lymph node metastasis and TNM stage (P < 0.001). Furthermore, miR-133a levels and TNM stage were independently associated with OS (HR = 0.590, 95%CI: 0.350-0.995, P < 0.05; and HR = 6.111, 95%CI: 1.029-36.278, P < 0.05, respectively).
CONCLUSION: The downregulation of miR-133a may play an important role in the progression of CRC and can be used as an independent factor to determine CRC prognosis.

Entities:  

Keywords:  Biomarker; Colorectal cancer; MicroRNA-133a; Prognosis; Real-time polymerase chain reaction

Mesh:

Substances:

Year:  2014        PMID: 25170220      PMCID: PMC4145774          DOI: 10.3748/wjg.v20.i32.11340

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  25 in total

Review 1.  The widespread regulation of microRNA biogenesis, function and decay.

Authors:  Jacek Krol; Inga Loedige; Witold Filipowicz
Journal:  Nat Rev Genet       Date:  2010-07-27       Impact factor: 53.242

2.  The functional significance of miR-1 and miR-133a in renal cell carcinoma.

Authors:  Kazumori Kawakami; Hideki Enokida; Takeshi Chiyomaru; Shuichi Tatarano; Hirofumi Yoshino; Ichiro Kagara; Takenari Gotanda; Tokushi Tachiwada; Kenryu Nishiyama; Nijiro Nohata; Naohiko Seki; Masayuki Nakagawa
Journal:  Eur J Cancer       Date:  2012-04       Impact factor: 9.162

3.  Cancer statistics, 2010.

Authors:  Ahmedin Jemal; Rebecca Siegel; Jiaquan Xu; Elizabeth Ward
Journal:  CA Cancer J Clin       Date:  2010-07-07       Impact factor: 508.702

4.  Differential miRNA expression profiles in bladder urothelial carcinomas.

Authors:  Tao Song; Wei Xia; Ningsheng Shao; Xu Zhang; Chunyang Wang; Yiguang Wu; Jun Dong; Wei Cai; Hongzhao Li
Journal:  Asian Pac J Cancer Prev       Date:  2010

Review 5.  MicroRNAs and cancer: past, present, and potential future.

Authors:  Kristen M Nelson; Glen J Weiss
Journal:  Mol Cancer Ther       Date:  2008-12       Impact factor: 6.261

6.  Tumor suppressor functions of miR-133a in colorectal cancer.

Authors:  Yujuan Dong; Junhong Zhao; Chung-Wah Wu; Lijing Zhang; Xiaodong Liu; Wei Kang; Wing-Wah Leung; Ning Zhang; Francis K L Chan; Joseph J Y Sung; Simon S M Ng; Jun Yu
Journal:  Mol Cancer Res       Date:  2013-05-30       Impact factor: 5.852

7.  The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer.

Authors:  H Yoshino; T Chiyomaru; H Enokida; K Kawakami; S Tatarano; K Nishiyama; N Nohata; N Seki; M Nakagawa
Journal:  Br J Cancer       Date:  2011-02-08       Impact factor: 7.640

8.  Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer.

Authors:  S Kojima; T Chiyomaru; K Kawakami; H Yoshino; H Enokida; N Nohata; M Fuse; T Ichikawa; Y Naya; M Nakagawa; N Seki
Journal:  Br J Cancer       Date:  2011-11-08       Impact factor: 7.640

9.  Loss of miR-133a expression associated with poor survival of breast cancer and restoration of miR-133a expression inhibited breast cancer cell growth and invasion.

Authors:  Zheng-sheng Wu; Chao-qun Wang; Ru Xiang; Xue Liu; Shan Ye; Xue-qing Yang; Gui-hong Zhang; Xiao-chun Xu; Tao Zhu; Qiang Wu
Journal:  BMC Cancer       Date:  2012-02-01       Impact factor: 4.430

10.  Down-regulation of miR-126 is associated with colorectal cancer cells proliferation, migration and invasion by targeting IRS-1 via the AKT and ERK1/2 signaling pathways.

Authors:  Yu Zhou; Xiao Feng; Ya-ling Liu; Shi-cai Ye; Hao Wang; Wen-kai Tan; Ting Tian; Yu-mei Qiu; He-sheng Luo
Journal:  PLoS One       Date:  2013-11-29       Impact factor: 3.240

View more
  10 in total

1.  Tissue micro-RNAs associated with colorectal cancer prognosis: a systematic review.

Authors:  Igor Lopes Dos Santos; Karlla Greick Batista Dias Penna; Megmar Aparecida Dos Santos Carneiro; Larisse Silva Dalla Libera; Jéssica Enocencio Porto Ramos; Vera Aparecida Saddi
Journal:  Mol Biol Rep       Date:  2021-02-17       Impact factor: 2.316

2.  The role of miR-370 and miR-138 in the regulation of BMP2 suppressor gene expression in colorectal cancer: preliminary studies.

Authors:  Agnieszka Piechowska; Celina Kruszniewska-Rajs; Magdalena Kimsa-Dudek; Magdalena Kołomańska; Barbara Strzałka-Mrozik; Joanna Gola; Stanisław Głuszek
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-15       Impact factor: 4.553

3.  Combined downregulation of microRNA-133a and microRNA-133b predicts chemosensitivity of patients with esophageal squamous cell carcinoma undergoing paclitaxel-based chemotherapy.

Authors:  Guiming Chen; Jin Peng; Weiguo Zhu; Guangzhou Tao; Yaqi Song; Xilei Zhou; Wanwei Wang
Journal:  Med Oncol       Date:  2014-10-04       Impact factor: 3.064

4.  The microRNA-325 inhibits hepatocellular carcinoma progression by targeting high mobility group box 1.

Authors:  Huifen Li; Weihua Huang; Rongcheng Luo
Journal:  Diagn Pathol       Date:  2015-07-22       Impact factor: 2.644

Review 5.  MicroRNAs as growth regulators, their function and biomarker status in colorectal cancer.

Authors:  Lina Cekaite; Peter W Eide; Guro E Lind; Rolf I Skotheim; Ragnhild A Lothe
Journal:  Oncotarget       Date:  2016-02-09

6.  Prognostic value of decreased microRNA-133a in solid cancers: a meta-analysis.

Authors:  Jian Xiao; Yong Zou; Xiaoxiao Lu; Bin Xie; Qiao Yu; Baimei He; Bixiu He; Qiong Chen
Journal:  Onco Targets Ther       Date:  2016-09-21       Impact factor: 4.147

7.  Colorectal adenoma and carcinoma specific miRNA profiles in biopsy and their expression in plasma specimens.

Authors:  Zsófia Brigitta Nagy; Barnabás Wichmann; Alexandra Kalmár; Orsolya Galamb; Barbara Kinga Barták; Sándor Spisák; Zsolt Tulassay; Béla Molnár
Journal:  Clin Epigenetics       Date:  2017-02-14       Impact factor: 6.551

8.  Validation of miRNA prognostic significance in stage II colorectal cancer: A protocol for systematic review and meta-analysis of observational clinical studies.

Authors:  Shanthi Sabarimurugan; Chellan Kumarasamy; Madhav Madurantakam Royam; Karthik Lakhotiya; Gothandam Kodiveri Muthukaliannan; Suja Ramalingam; Rama Jayaraj
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

9.  Prognostic value of microRNAs in colorectal cancer: a meta-analysis.

Authors:  Song Gao; Zhi-Ying Zhao; Rong Wu; Yue Zhang; Zhen-Yong Zhang
Journal:  Cancer Manag Res       Date:  2018-04-30       Impact factor: 3.989

10.  Extensive screening of microRNA populations identifies hsa-miR-375 and hsa-miR-133a-3p as selective markers for human rectal and colon cancer.

Authors:  David Weber; Laurence Amar; Daniel Gödde; Christian Prinz
Journal:  Oncotarget       Date:  2018-06-05
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.